Last reviewed · How we verify

NCT03058627: NOTION-3

Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation

Active, enrolled NA Last updated 19 December 2023
What this trial tests

NA trial testing PCI in Coronary Artery Disease in 454 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 September 2017
Primary endpoint
15 January 2024
15 November 2027

Quick facts

Lead sponsorThomas Engstrom
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment454
Start date15 September 2017
Primary completion15 January 2024
Estimated completion15 November 2027
Sites12 locations across Denmark, Finland, Sweden, Latvia

Drugs / interventions tested

Conditions studied

Sponsor

Thomas Engstrom — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effect of routine FFR-guided complete revascularization with PCI compared to conservative management in patients with concomitant coronary artery disease who are undergoing TAVI.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
    Lønborg J, Jabbari R, Sabbah M, Veien KT, et al · · 2024 · cited 73× · PMID 39216095 · DOI 10.1056/nejmoa2401513
  2. Long-Term Effects of Transcatheter Aortic Valve Implantation on Coronary Hemodynamics in Patients With Concomitant Coronary Artery Disease and Severe Aortic Stenosis.
    Vendrik J, Ahmad Y, Eftekhari A, Howard JP, et al · · 2020 · cited 40× · PMID 32102615 · DOI 10.1161/jaha.119.015133
  3. Comparison of Outcomes After Transcatheter Aortic Valve Replacement vs Surgical Aortic Valve Replacement Among Patients With Aortic Stenosis at Low Operative Risk.
    Virtanen MPO, Eskola M, Jalava MP, Husso A, et al · · 2019 · cited 38× · PMID 31199448 · DOI 10.1001/jamanetworkopen.2019.5742
  4. Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.
    Aarts HM, van Hemert ND, Meijs TA, van Nieuwkerk AC, et al · · 2023 · cited 21× · PMID 37910336 · DOI 10.1007/s12471-023-01824-w
  5. Coronary Microcirculation in Aortic Stenosis: Pathophysiology, Invasive Assessment, and Future Directions.
    Zelis JM, Tonino PAL, Pijls NHJ, De Bruyne B, et al · · 2020 · cited 20× · PMID 32774184 · DOI 10.1155/2020/4603169
  6. To revascularize or not before transcatheter aortic valve implantation?
    Perez S, Thielhelm TP, Cohen MG. · · 2018 · cited 15× · PMID 30505538 · DOI 10.21037/jtd.2018.09.85
  7. Combined CT Coronary Artery Assessment and TAVI Planning.
    Renker M, Schoepf UJ, Kim WK. · · 2023 · cited 14× · PMID 37046545 · DOI 10.3390/diagnostics13071327
  8. Non-hyperaemic pressure ratios to guide percutaneous coronary intervention.
    Michail M, Thakur U, Mehta O, Ramzy JM, et al · · 2020 · cited 14× · PMID 33004619 · DOI 10.1136/openhrt-2020-001308

Verify or expand the search:

Other trials of PCI

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Thomas Engstrom trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03058627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing